The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The PRIOH-1 study met its primary endpoint, delivering statistically significant and clinically meaningful improvements in lesion healing
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
Immunology remained AbbVie’s largest and fastest-growing segment, delivering $30.41 billion in global net revenues,
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
The new service delivers end-to-end support, managing every stage of an epigenomics project
Subscribe To Our Newsletter & Stay Updated
